Company intelligence / Profile preview

Biocomposites

Keele, England, United Kingdombiocomposites.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biocomposites’ products are used in over one million procedures annually across more than 100 countries. The company’s calcium compound-based devices and cements are clinically proven to regenerate bone and manage infection risks in orthopaedic and trauma surgeries. In recent years, the portfolio expanded with the acquisition of NanoBone technology for advanced synthetic bone grafting.

Therapeutic areas: OtherNeurologyInfectious Diseases
Modalities: DeviceBiomaterialSynthetic bone grafts
Industry: Surgical Medical Devices

Drug pipeline

2 assets

STIMULAN

Commercial

Indications: Bone infection, Soft tissue infection

1 more asset in the full pipeline.

Request access →

Partnerships

Distribution partnerships globally; no major pharma/biotech R&D alliances disclosed

Beyond the preview

Go deeper on Biocomposites.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocomposites.

Explore the full profile